Our top pick for
Building a portfolio
Kiniksa Pharmaceuticals, Ltd is a biotechnology business based in the US. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Kiniksa Pharmaceuticals employs 168 staff and has a market cap (total outstanding shares value) of USD$1.5 billion.
|52-week range||USD$11.51 - USD$26.135|
|50-day moving average||USD$21.8312|
|200-day moving average||USD$18.5381|
|Wall St. target price||USD$34|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.339|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Kiniksa Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kiniksa Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Kiniksa Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Kiniksa Pharmaceuticals shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$0|
|Return on assets TTM||-32.57%|
|Return on equity TTM||-60.07%|
|Market capitalisation||USD$1.5 billion|
TTM: trailing 12 months
There are currently 3.9 million Kiniksa Pharmaceuticals shares held short by investors – that's known as Kiniksa Pharmaceuticals's "short interest". This figure is 2.1% up from 3.8 million last month.
There are a few different ways that this level of interest in shorting Kiniksa Pharmaceuticals shares can be evaluated.
Kiniksa Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Kiniksa Pharmaceuticals shares currently shorted divided by the average quantity of Kiniksa Pharmaceuticals shares traded daily (recently around 347488.4097035). Kiniksa Pharmaceuticals's SIR currently stands at 11.13. In other words for every 100,000 Kiniksa Pharmaceuticals shares traded daily on the market, roughly 11130 shares are currently held short.
However Kiniksa Pharmaceuticals's short interest can also be evaluated against the total number of Kiniksa Pharmaceuticals shares, or, against the total number of tradable Kiniksa Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kiniksa Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Kiniksa Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.1364% of the tradable shares (for every 100,000 tradable Kiniksa Pharmaceuticals shares, roughly 136 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kiniksa Pharmaceuticals.
Find out more about how you can short Kiniksa Pharmaceuticals stock.
We're not expecting Kiniksa Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Kiniksa Pharmaceuticals's shares have ranged in value from as little as $11.51 up to $26.135. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiniksa Pharmaceuticals's is 0. This would suggest that Kiniksa Pharmaceuticals's shares are less volatile than average (for this exchange).
Kiniksa Pharmaceuticals, Ltd. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.